State Administrative Expenses

Haynes International, Inc. Reports Fourth Quarter Fiscal 2023 Financial Results and Year End Highlights

Retrieved on: 
Giovedì, Novembre 16, 2023
IGT, Holiday, EBITDA, Haynes International, Ageing, Exercise, Traction, Tax, Public expenditure, Research, Calendar, Capital, Credit, Growth, State Administrative Expenses, Borrowing base, Life, CPI, Pharmaceutical industry, Film industry, Security (finance), Holding company, Tobacco, Video game, Recycling, Finance

Selling, general and administrative expense as a percent of net revenues decreased from 8.4% in the fourth quarter of fiscal 2022 to 7.8% in the fourth quarter of fiscal 2023, largely driven by the higher net revenues in the fourth quarter of fiscal 2023.

Key Points: 
  • Selling, general and administrative expense as a percent of net revenues decreased from 8.4% in the fourth quarter of fiscal 2022 to 7.8% in the fourth quarter of fiscal 2023, largely driven by the higher net revenues in the fourth quarter of fiscal 2023.
  • Income tax expense in the fourth quarter of fiscal 2023 as a percentage of income before income taxes was 11.5% as compared to 15.3% in the fourth quarter of fiscal 2022.
  • Revenue and earnings in the first quarter of fiscal 2024 are expected to be higher compared to the first quarter of fiscal 2023, but lower than the fourth quarter of fiscal 2023.
  • The Company will host a conference call on Friday, November 17, 2023 to discuss its results for the fourth quarter of fiscal 2023.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Lunedì, Novembre 20, 2023
Health, Infectious Diseases, COVID-19, Clinical Trials, Research, Science, Pharmaceutical, Sale, Heart, Southampton General Hospital, Pediatrics, Patient, Conference, Doctor of Philosophy, Viral, Webcast, Safety, RSV, Human, Respiratory system, MBBS, Federal, Chronic obstructive pulmonary disease, Texas A&M University, O'Driscoll (surname), Dean (education), Respiratory Medicine, Pharmacokinetics, University, FRCP, Fast Track, Asthma, Medication, Infection, FERS, Urinary tract infection, Virology, Ageing, Upper respiratory tract infection, Viral load, Clinical trial, Tax, HBV, FDA, Vaccine, Faculty, OMERS, HCV, State Administrative Expenses, Pharmaceutical industry, Life insurance, Cryptocurrency, Pfizer, Cantab, FIDSA, FAAP, Medicine, MD

(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.

Key Points: 
  • (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.
  • For the twelve months ended September 30, 2023, total revenue was $79.2 million compared to $86.2 million for the same period in 2022.
  • The decrease in the quarter and in year-over-year revenue is due to a decline in AbbVie’s sales of MAVYRET®/MAVIRET®.
  • Non-cash interest expense was $3.2 million for the three months ended September 30, 2023 and $5.1 million for the twelve months ended September 30, 2023.

Sally Beauty Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Results

Retrieved on: 
Martedì, Novembre 14, 2023
Teens, Women, Men, Specialty, Family, Fashion, Lifestyle, Consumer, Cosmetics, Retail, BSG, Pressure, Sally, Acquisition, NYSE, SOFR, Human, International, Share repurchase, SBH, Consultant, Amika Shail, Sally Beauty Holdings, Capital, Capital expenditure, COVID-19, GAAP, Adjustment, Zero balance account, Central Time, Forecasting, Growth, State Administrative Expenses, Goldwell, Cryptocurrency, Arms industry, Bank, Commercial property, Marketing, Video game, Pharmaceutical industry, Textile

“Our teams are executing well on our strategic initiatives designed to reignite top line growth and improve profitability -- enhancing our customer centricity, growing our high margin own brands and amplifying innovation, and increasing the efficiency of our operations. Building on our strong foundation, we are focused on the future and remain committed to creating value for our shareholders.”

Key Points: 
  • Sally Beauty Holdings, Inc. (NYSE: SBH) (“the Company”), the leader in professional hair color, today announced financial results for its fourth quarter and full year ended September 30, 2023.
  • The acquisition is expected to result in an incremental sales benefit of approximately 1% to the Company’s Beauty Systems Group segment in fiscal 2024.
  • Fourth quarter consolidated net sales were $921.4 million, a decrease of 4.3% compared to the prior year.
  • Consolidated gross profit for the fourth quarter was $466.6 million compared to $463.5 million in the prior year, an increase of 0.7%.

Antibe Reports Q2 2024 Interim Financial and Operating Results

Retrieved on: 
Lunedì, Novembre 13, 2023
Biotechnology, Health, Clinical Trials, Safety, IP, OTCQX, Bank statement, Hydrogen sulfide, Administration, Research, Phase II, SEDAR, Hand, MD, Development, Phase, Family, State Administrative Expenses, Antibe Therapeutics, TSX, Inflammation, Patent, Pharmaceutical industry

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2023.

Key Points: 
  • Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2023.
  • While trial initiation remains set for calendar Q1 2024, the Company now anticipates top-line results in calendar Q3 2024.
  • General and Administrative Expenses: General and administrative expenses were $1.9 million, compared to $1.7 million in fiscal Q2 2023.
  • The Company’s unaudited fiscal Q2 2024 condensed interim financial statements and MD&A are available on SEDAR.

Orion Office REIT Inc. Announces Third Quarter 2023 Results

Retrieved on: 
Giovedì, Novembre 9, 2023
Professional Services, Other Construction & Property, Commercial Building & Real Estate, Finance, Construction & Property, REIT, Webcast, Acquisition, NYSE, Depreciation, Share repurchase, Government, Real estate, Investment, ONL, GAAP, Adjustment, Tax, State Administrative Expenses, Orion, Debt, Property management, Holding company, Security (finance), Reinsurance, Walgreens

Orion Office REIT Inc. (NYSE: ONL) (“Orion” or the “Company”), a fully-integrated real estate investment trust focused on the ownership, acquisition and management of single-tenant net lease office properties located across the U.S., announced today its operating results for the third quarter ended September 30, 2023.

Key Points: 
  • Orion Office REIT Inc. (NYSE: ONL) (“Orion” or the “Company”), a fully-integrated real estate investment trust focused on the ownership, acquisition and management of single-tenant net lease office properties located across the U.S., announced today its operating results for the third quarter ended September 30, 2023.
  • The Company’s net loss attributable to common stockholders was $(16.5) million, or $(0.29) per share, during the third quarter of 2023, as compared to $(53.0) million, or $(0.94) per share, reported in the same quarter of 2022.
  • Core FFO for the third quarter of 2023 was $24.1 million, or $0.43 per share, as compared to $25.6 million, or $0.45 per share in the same quarter of 2022.
  • The Company’s 2023 General and Administrative Expenses guidance range of $18.25 million to $18.75 million is unchanged from last quarter.

BZAM Ltd. Reports Third Quarter 2023 Results

Retrieved on: 
Martedì, Novembre 28, 2023
EBITDA, Absorption, Facility, Stock, SG&A, G&A, Adjustment, Stone pine, State Administrative Expenses, Certification, Video game, Q2, Q3

Direct Gross Profit: Direct Gross Profit for the quarter was 8% before changes in fair value of biological assets, compared to 6% in Q3 2022 and 16% in Q2 2023.

Key Points: 
  • Direct Gross Profit: Direct Gross Profit for the quarter was 8% before changes in fair value of biological assets, compared to 6% in Q3 2022 and 16% in Q2 2023.
  • Adjusted General and Administrative Expenses ("G&A"): Adjusted G&A increased year-over-year by $2.5 million or 59% primarily due to the BZAM Transaction, and increased by $0.51 million from Q2, 2023, or 8%.
  • In Q3 2023, the Company received orders under its international distribution agreements in Germany, Australia, and the United Kingdom following on receipt of its EU-GMP certification in Q2 2023.
  • On October 27, 2023, the Company entered into a Waiver Agreement with its lender, waiving the covenant requiring positive EBITDA until January 31, 2024.

Yatsen Announces Third Quarter 2023 Financial Results and Upsizing and Extension of Share Repurchase Program

Retrieved on: 
Martedì, Novembre 21, 2023
Research, NYSE, Perfect, Double, Investment, Share repurchase, Federal Reserve, ADS, Marketing, RMB, YSG, Call, H.10, Translation, Abby, Florida Board of Governors, Total, Operating cost, Skin care, State Administrative Expenses, Cryptocurrency, Pharmaceutical industry, Video game, Bank, Renminbi, Conference

GUANGZHOU, China, Nov. 21, 2023 /PRNewswire/ -- Yatsen Holding Limited ("Yatsen" or the "Company") (NYSE: YSG), a leading China-based beauty group, today announced its unaudited financial results for the third quarter ended September 30, 2023, and upsizing and extension of the share repurchase program.

Key Points: 
  • Gross margin for the third quarter of 2023 was 71.4%, as compared with 68.9% for the prior year period.
  • Net loss for the third quarter of 2023 decreased by 6.1% to RMB197.9 million (US$27.1 million) from RMB210.7 million for the prior year period.
  • Our clinical and premium skincare brands, including Galénic, DR.WU and Eve Lom, recorded growth in combined net revenues for another quarter.
  • Gross margin for the third quarter of 2023 increased to 71.4% from 68.9% for the prior year period.

Full Truck Alliance Co. Ltd. Announces Third Quarter 2023 Unaudited Financial Results

Retrieved on: 
Lunedì, Novembre 20, 2023
Form 6-K, FTA, Marex (British company), NYSE, Form, Investment, Share repurchase, Maus, Tax, Federal Reserve, ADS, Research, Calendar, Marketing, RMB, Advertising, H.10, GAAP, Translation, Florida Board of Governors, Growth, State Administrative Expenses, Video game, Beauty salon, Warehouse, Bank, Broker, Cryptocurrency, Pharmaceutical industry, Real estate, VAT

GUIYANG, China, Nov. 20, 2023 /PRNewswire/ -- Full Truck Alliance Co. Ltd. ("FTA" or the "Company") (NYSE: YMM), a leading digital freight platform, today announced its unaudited financial results for the third quarter ended September 30, 2023.

Key Points: 
  • GUIYANG, China, Nov. 20, 2023 /PRNewswire/ -- Full Truck Alliance Co. Ltd. ("FTA" or the "Company") (NYSE: YMM), a leading digital freight platform, today announced its unaudited financial results for the third quarter ended September 30, 2023.
  • Fulfilled orders[2] in the third quarter of 2023 reached 42.5 million, an increase of 27.0% from 33.5 million in the same period of 2022.
  • See "Use of Non-GAAP Financial Measures" and "Reconciliations of GAAP and Non-GAAP Results" at the end of this press release.
  • The Company's management will hold an earnings conference call at 7:00 A.M. U.S. Eastern Time on November 20, 2023, or 8:00 P.M. Beijing Time to discuss its financial results and operating performance for the third quarter of 2023.

Pixie Dust Technologies, Inc. Announces Fiscal Year 2023 Financial Results

Retrieved on: 
Venerdì, Novembre 17, 2023
Television, Ventilation, Research, Chewy (company), Bank statement, Annual report, Radio, Florida Board of Governors, Insurance, Air conditioning, Federal Reserve, USD, Marketing, Movement, Advertising, COVID-19, Bell, Translation, IPO, Hand, Software, Atmosphere, Speech, Car, Total revenue, State Administrative Expenses, Shionogi, Scalp, Rare-earth element, Mobile phone, Cryptocurrency, Pharmaceutical industry

NEW YORK and TOKYO, Nov. 17, 2023 /PRNewswire/ - Pixie Dust Technologies, Inc. (Nasdaq: PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave technology, today announced its financial results for the fiscal year ended April 30, 2023.

Key Points: 
  • NEW YORK and TOKYO, Nov. 17, 2023 /PRNewswire/ - Pixie Dust Technologies, Inc. (Nasdaq: PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave technology, today announced its financial results for the fiscal year ended April 30, 2023.
  • Product Sales were approximately ¥182.9 million ($1.3 million) in the fiscal year ended April 30, 2023, representing a 100% increase from the prior year.
  • Services Sales declined to ¥521.8 million ($3.8 million) in the fiscal year ended April 30, 2023 from ¥636.3 million ($4.7 million) in the prior year.
  • Net Loss was ¥2.0 billion ($14.5 million) in the fiscal year ended April 30, 2023 compared to ¥1.1 billion ($8.2 million) in the prior year.

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Giovedì, Novembre 9, 2023
Priority review, FDA, Ageing, PDUFA, Addition, Rare, Physician, Christophe, SG, MD, Conference, Organization, Doctor of Philosophy, PRV, Primary immunodeficiency, R, Society, Neutropenia, ASH, Wart, WHIM, Disease, ID, WHIM syndrome, Immune system, Research and development, Line, File, Security (finance), New Drug Application, NDA, Safety, Conference call, Patient, Diagnosis, State Administrative Expenses, Pharmaceutical industry, Rare-earth element, Hypogammaglobulinemia, Infection, Myelokathexis

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2023 and highlighted key recent and upcoming expected milestones.

Key Points: 
  • ET
    BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2023 and highlighted key recent and upcoming expected milestones.
  • The FDA has notified X4 that it does not currently plan to hold an advisory committee meeting to review the filing.
  • Cash, Cash Equivalents, Restricted Cash, and Short-Term Marketable Securities: X4 had $142.7 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2023.
  • The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .